Clinical trials: CD
Crohn's Disease
Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease
Primary objective: Assessment of the efficacy of EryDex vs PLACEBO in maintaining patients with steroid-dependent Crohn's disease in clinical remission throughout 12 months without oral steroids. Secondary objectives: 1.
- Trial name
- Crodex (NCT01277289)
- Testing
- Dexamethasone
- Where
- 8 sites in Italy, Romania and 1 more
- Volunteers
- 51 people
- Sponsor
- Quince Therapeutics S.p.A.
CD - Crohn's Disease, Stricture; Bowel
Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
This study intends to select patients with confirmed moderate-to-severe Crohn's disease (CD) and obstructive symptoms of intestinal stenosis, who have clear evidence of lumen stenosis caused by the disease itself through…
- Conditions
- CD - Crohn's Disease, Stricture; Bowel, IBD - Inflammatory Bowel Disease
- Trial name
- NCT07444060
- Testing
- Guselkumab (GUS), Ustekinumab (UST)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Crohn's Disease (CD)
Unraveling the Blood Microbiome in Postoperative Recurrence of Crohn's Disease
Crohn's disease, a chronic inflammation of the gastro-intestinal tract, is a disease with a complex pathogenetic background. Hereditary factors, environmental factors and the gut flora play a varying role in its onset, however…
- Trial name
- IBDbloom (NCT06770140)
- Where
- Netherlands
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Crohn's Disease
Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)
The purpose of this study is to evaluate the efficacy and safety of ontamalimab as maintenance treatment in participants with moderate to severe Crohn's disease (CD).
- Trial name
- CARMEN CD 307 (NCT03627091)
- Testing
- Ontamalimab
- Where
- 281 sites in United States, Argentina and 32 more
- Volunteers
- 40 people
- Sponsor
- Shire
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Diagnosis and Physiopathology of Insulin Allergy
Insulin allergy (IA) is still observed even with recombinant human insulin and insulin analogs. Obviously, the usual attitude facing an allergy, i. e.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Hypersensitivity, Immediate Hypersensitivity
- Trial name
- Allerdiab (NCT01407640)
- Testing
- Allergy tests
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Crohn Disease
Surgery vs Biologics for Treating Stricturing CD--a RCT
The management of stricturing Crohn's disease (CD) remains challenging. Although surgical resection may be the final way to solve it, the efficacy of biologics for symptomatic CD associated strictures was acceptable.
- Trial name
- NCT05421455
- Testing
- Group A, Group B
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Zhu Weiming
Conduct Disorder, Mentalization Based Therapy
Using Mentalization Based Therapy to Support Children and Adolescents Referred to Specialist Mental Health Services in the NHS for Aggressive and/or Violent Behaviour
The MICA Study is a research project that has been designed to work out how helpful mentalisation based therapy is. This is a new type of support that helps young people make sense of their own behaviours and feelings, and those…
- Conditions
- Conduct Disorder, Mentalization Based Therapy, Violent Behavior, Aggressive Behaviour
- Trial name
- MICA (NCT07091721)
- Testing
- Mentalization based therapy (MBT), Support as usual
- Where
- 8 sites in United Kingdom
- Volunteers
- 632 people
- Sponsor
- Anna Freud
Crohn's Disease (CD)
The Impact of Time Restricted Feeding in Crohn's Disease
Time-restricted feeding (TRF) is a dietary regimen involving the consumption of food and liquids within a defined time window with or without additional restriction on dietary composition.
- Trial name
- TRF-CD (NCT04271748)
- Testing
- Time Restricted Feeding
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Weill Medical College of Cornell University
Lack of; Attention, With Hyperactivity (ADHD)
Treatment Plan for ADHD With Indifferent Traits
For children with ADHD aged 4-10 at the time of enrollment, starting from preschool, focusing on apathy and emotional control, using psycho-behavioral measurements, EEG experiments, and eye tracking technology to evaluate and…
- Trial name
- NCT05075447
- Testing
- Emotion Control Treatment Program
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Ulcerative Colitis (UC), Crohn Disease (CD)
Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease
Crohn\'s Disease (CD) and Ulcerative Colitis (UC) are chronic inflammatory bowel diseases (IBD). Risankizumab is a human monoclonal antibody against IL23 p19, part of a pro-inflammatory cytokine that mediates the inflammatory…
- Trial name
- NAVIGATE (NCT06606808)
- Testing
- Risankizumab-800CW 4.5 mg, Risankizumab-800CW 15 mg, Risankizumab-800CW 25 mg
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- University Medical Center Groningen
Recurrent Clostridium Difficile Infection
Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea
This study will assess the safety of a new biologic drug, RBX2660 (microbiota suspension) as a treatment for recurrent Clostridium difficile-associated diarrhea (CDAD), which is the primary symptom of recurrent Clostridium…
- Trial name
- PUNCH CD (NCT01925417)
- Testing
- RBX2660 (microbiota suspension)
- Where
- 13 sites in United States
- Volunteers
- 34 people
- Sponsor
- Rebiotix Inc.
Idiopathic Parkinson's Disease
Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease
The objective of this study is to compare the pharmacokinetics and pharmacodynamics of IPX054, carbidopa-levodopa immediate-release tablets, and carbidopa-levodopa controlled-release tablets in subjects with idiopathic…
- Trial name
- NCT00279825
- Testing
- IPX054 200 mg, IPX054 250 mg, CD-LD IR
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Impax Laboratories, LLC
Relapsed Adult Myeloid Leukemia, Chemotherapy Refractory Adult Myeloid Leukemia
Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
- Trial name
- CART33 (NCT01864902)
- Testing
- CART33 cells, anti-CD33 CART, anti-CD33 CAR T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Chinese PLA General Hospital
Crohn's Disease
Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)
The purpose of this study is to determine whether mesalazine or budesonide is more active in the treatment of active Crohn's disease.
- Trial name
- NCT00300118
- Testing
- budesonide, mesalazine
- Where
- Germany
- Volunteers
- 311 people
- Sponsor
- Dr. Falk Pharma GmbH
Digestive System Disease, Inflammatory Bowel Diseases
Comparative Study of Intestinal Color Ultrasound and Capsule Endoscopy in Monitoring Crohn's Disease
The disease activity index under intestinal color ultrasound was evaluated by SUS-CD, and the disease activity index under capsule endoscopy was evaluated by CECDAI.
- Conditions
- Digestive System Disease, Inflammatory Bowel Diseases, Crohn Disease, Crohn Disease of Small Intestine
- Trial name
- NCT05636657
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Decompensated Heart Failure
Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure
The primary objective of the study is to assess the safety and tolerability of IV administration of CD-NP and the dose relationship of CD-NP on improvement of clinical symptoms and renal function in ADHF patients.
- Trial name
- NCT00839007
- Testing
- CD-NP
- Where
- 21 sites in United States, Germany and 1 more
- Volunteers
- 77 people
- Sponsor
- Nile Therapeutics
Colitis, Ulcerative, Crohn Disease
A Study to Assess the Effectiveness and Safety of Treatment With Vedolizumab in Adult Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real Life
The purpose of this study is to describe in real life the effectiveness of treatment with vedolizumab.
- Conditions
- Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases
- Trial name
- GEVOL (NCT03378388)
- Where
- 13 sites in France
- Volunteers
- 29 people
- Sponsor
- Takeda
Left Ventricular Insufficiency
Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients
The most promising chimeric natriuretic peptide designed and studied by our group has been CD-NP which has anti-fibrotic and cardioprotective properties in vivo, vitro and in normal volunteers and human heart failure patients.
- Trial name
- NCT01750905
- Testing
- CD-NP
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Mayo Clinic
Crohn's Disease
COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial)
The primary objective is to compare the efficacy and safety of infliximab plus methotrexate to infliximab alone for the long-term control of signs and symptoms of Crohn's disease (CD) in patients with symptoms that are persistent…
- Trial name
- NCT00132899
- Testing
- Methotrexate
- Where
- Canada
- Volunteers
- 128 people
- Sponsor
- University of Western Ontario, Canada
Parkinson's Disease
A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004
The purpose of this study is to allow evaluation of long-term clinical effect and safety outcome of treatment with AP-CD/LD, as well as to allow patients to benefit from extended treatment duration with AP-CD/LD after they have…
- Trial name
- NCT02615873
- Testing
- Accordion Pill™ Carbidopa/Levodopa
- Where
- 85 sites in United States, Bulgaria and 8 more
- Volunteers
- 460 people
- Sponsor
- Intec Pharma Ltd.